Bayer AG

BAYN

DE000BAY0017

Pharmaceuticals

Real-time Estimate Tradegate Other stock markets 04:14:39 2024-05-09 am EDT			5-day change	1st Jan Change
28.35 ^EUR	-0.45%		+0.62%	-15.83%

07:30am	War upends Ukraine's economy in a shift that may be permanent	RE
May. 08	Bayer to present new data at ACOG	CF

Bayer Aktiengesellschaft: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]

July 23, 2019 at 02:05 am EDT

DGAP Preliminary announcement financial reports: Bayer Aktiengesellschaft / Preliminary announcement on the disclosure of financial statements
Bayer Aktiengesellschaft: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]

23.07.2019 / 08:00
Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Bayer Aktiengesellschaft hereby announces that the following financial reports shall be disclosed :

Report: Financial report of the group (half-year/Q2) Date of disclosure / German: July 30, 2019 Date of disclosure / English: July 30, 2019 German: https://www.quartalsbericht-2019-q2.bayer.de English: https://www.quarterly-report-2019-q2.bayer.com

23.07.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:	English
Company:	Bayer Aktiengesellschaft
	Kaiser-Wilhelm-Allee 1
	51373 Leverkusen
	Germany
Internet:	www.bayer.com


End of News	DGAP News Service

770441 23.07.2019

Latest news about Bayer AG

War upends Ukraine's economy in a shift that may be permanent	01:30am	RE
Bayer to present new data at ACOG	May. 08	CF
Bayer to Unveil Late-Breaking Data from Phase Iii Oasis 1 and 2 for Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause	May. 08	CI
Companies take a stand against extremism and racism	May. 07	DP
BAYER AG : UBS sticks Neutral	May. 06	ZD
Singtel Taps Head of Australia's Broadband Operator for Optus -- Update	May. 05	DJ
Singtel-owned Optus names broadband network boss Stephen Rue as new CEO	May. 05	RE
Singtel Taps Australian National Broadband Network CEO to Head Optus	May. 05	DJ
European Equities Close Mostly Lower in Thursday Trading; Eurozone Manufacturing Remains in Contraction	May. 02	MT
Manufacturing Downturn Keeps German Stocks Lower	May. 02	MT
BridgeBio Pharma Shares Decline After Q1 Financial Results	May. 02	MT
BAYER AG : Barclays reiterates its Neutral rating	May. 02	ZD
Bayer Shares Surge After Monsanto Appeal Win	May. 02	DJ
Bayer at high since early April after US court victory	May. 02	DP
Jefferies rates Bayer a 'Hold' - Target 29 euros	May. 02	DP
Bayer: Monsanto wins U.S. appeal	May. 02	CF
European shares struggle for direction in earnings tide, Fed decision	May. 02	RE
BAYER AG : Jefferies gives a Neutral rating	May. 02	ZD
US Ruling Requires Bayer to Face Antitrust Lawsuit Over Flea Treatment	May. 02	MT
US Court Overturns $185 Million PCB Contamination Verdict Against Bayer's Monsanto	May. 01	MT
Bayer's Monsanto wins reversal of $185 million PCBs verdict in Washington court	May. 01	RE
BAYER : Another year of patience needed	May. 01
Bayer: strategic collaboration with Evotec	Apr. 30	CF
Evotec, Bayer to Collaborate on New Cardiovascular Disease Therapies	Apr. 30	MT
Evotec, Bayer to Focus on Precision Treatments for Cardiovascular Diseases	Apr. 30	MT

Chart Bayer AG

Duration

Period

More charts

Company Profile

Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (48.8%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (38%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.7%); - other (0.5%). Net sales are distributed geographically as follows: Germany (5.1%), Switzerland (1.2%), Europe-Middle East-Africa (23.2%), the United States (30.6%), North America (3.5%), China (7.6%), Asia-Pacific (10%), Brazil (10.4%) and Latin America (8.4%).

Sector

Pharmaceuticals

Calendar

2024-05-14 - Q1 2024 Earnings Release

Related indices

EURO STOXX 50 , STOXX EUROPE 600 (EUR) , DAX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

BAYER : Another year of patience needed

May 01, 2024 at 11:38 am EDT

Bayer AG: Not out of the woods yet

March 06, 2024 at 10:46 am EST

More Strategies

Ratings for Bayer AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

28.48 EUR

Average target price

36.9 EUR

Spread / Average Target

+29.60%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BAYER AG	-15.46%	30.06B
ELI LILLY AND COMPANY	+32.95%	698B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.97%	358B
MERCK & CO., INC.	+18.83%	328B
ABBVIE INC.	+3.54%	283B
ASTRAZENECA PLC	+15.66%	238B
NOVARTIS AG	+6.68%	203B
ROCHE HOLDING AG	-9.08%	198B
AMGEN INC.	+6.70%	165B

Other Pharmaceuticals

Bayer AG

Equities

BAYN

DE000BAY0017

Pharmaceuticals

Bayer Aktiengesellschaft: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]

EPS Revisions